آنتی­ بادی WT1 (Wilms Tumor) (6F-H2)

(Name: WT-1 (Wilm´s Tumour Protein 1)Antibody (Clone 6F-H2

Description and aplications: WT-1 gene is located on chromosome 11p13 and is involved in the development of Wilm´s tumor (WT). WT is associated with mutations of WT1, a zinc-finger transcription factor that is essential for the development of the metanephric kidney and the urogenital system. The WT1 gene is normally expressed in fetal kidney and mesothelium, and its expression has been suggested as a marker for Wilms tumor and mesothelioma. Anti-WT1 is useful in the diagnosis of malignant mesotheliomas (nuclei) while the nuclei of lung adenocarcinomas are not labeled with this product. However, cytoplasmic labeling of lung adenocarcinomas
may be observed. Anti-WT1 labels 93% of serousovarian carcinomas and 0% (nuclei) of mucinous carcinomas of the ovary and pancreato-biliary carcinomas. Anti-WT1 can  also be utilized in the differential diagnosis of small round cell tumors as 100% of desmoplastic small round cell tumors and 70% of nephroblastomas (Wilm’s tumor) are positive (nuclei) for this marker. Tumors such as Ewings sarcoma/PNET, neuroblastomas, rhabdomyosarcomas, and rhabdoid tumors are negative. Occasionally cytoplasmic labeling may be seen in these tumors, however.

Composition: anti-human WT-1 mouse monoclonal antibody obtained from tissue culture supernatant prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide.

Immunogen: Truncated human WT1 protein corresponding to aa 1-181.